As SK Bioscience is poised to contribute to the world’s prolonged battle against the COVID-19 pandemic with its SKYCovione vaccine, the South Korean vaccine maker has underlined the importance of global partnerships in developing the country’s first homemade COVID-19 vaccine.

SK Bioscience joined hands with the Institute for Protein Design at the University of Washington School of Medicine to develop SKYCovione, a self-assembled nanoparticle vaccine. The development process was also supported by multinational pharmaceutical giant GSK’s pandemic adjuvant. An adjuvant added to a vaccine can improve the immune system’s response to the vaccine.